---
title: "Subscribers"
description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member."
url: "https://cbrneworld.com/news/subscribers?start=1105"
date: "2026-07-31T12:45:10+00:00"
language: "en-GB"
---

[![](https://cbrneworld.com/templates/yootheme/cache/7d/FDA_Logo-7dbc03a4.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1350:first-medical-product-cleared-in-u-s-for-use-on-certain-injuries-caused-by-sulfur-mustard&catid=12)

##  [First medical product cleared in U.S. for use on certain injuries caused by sulfur mustard](https://cbrneworld.com/index.php?option=com_content&view=article&id=1350:first-medical-product-cleared-in-u-s-for-use-on-certain-injuries-caused-by-sulfur-mustard&catid=12)

 Written by Zoe Rutherford on 23 July 2019.

The U.S. government reached a milestone in its long-standing efforts to defend the country against potential use of chemical weapons: the first U.S. Food and Drug Administration ([FDA](https://www.fda.gov/)) [clearance of a product](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K190343) to manage certain blister injuries caused by sulfur mustard, commonly known as mustard gas.

“Our top priority is saving lives during national emergencies. To do so, we must make safe and effective medical products for all the illnesses and injuries stemming from the serious health security threats confronting our nation,” said Robert Kadlec, M.D., Assistant Secretary for Preparedness and Response ([ASPR](https://www.phe.gov/)) at U.S. Department of Health and Human Services. “This product clearance is the latest step in delivering on that promise to the American people.”

The ASPR’s Biomedical Advanced Research and Development Authority ([BARDA](https://www.phe.gov/barda)) provided technical expertise and funding to support the studies necessary to show that the product, Silverlon, is appropriate for use on first- and second-degree skin burns caused by exposure to sulfur mustard.

“Chemical weapons like sulfur mustard cause horrific, painful, and life-altering injuries, yet in the 100-year history of sulfur mustard use, no medical countermeasures existed – until now,” added BARDA Director Rick Bright, Ph.D. “At BARDA, we are excited to have supported the first cleared product for use on skin injuries caused by sulfur mustard. This clearance exemplifies BARDA’s ongoing commitment to our partners and the nation as we seek out promising technologies and products to improve our nation’s health security and protect Americans.”

Argentum Medical, LLC, has received FDA clearances for multiple indications for Silverlon since 2003 and in that time the wound dressing has been used extensively by the U.S. military to treat burn and blast wounds. Silverlon dressings also are used widely by the healthcare and first responder communities.

“The FDA plays an important role in preparing our nation for a range of threats, including chemical, biological, radiological, and nuclear threats, providing guidance and support for the development of medical countermeasures that can be used safely, effectively and reliably during public health emergencies,” said Acting FDA Commissioner Ned Sharpless, M.D. “The expanded indication for this first-of-its-kind wound contact dressing to include management of certain injuries caused by sulfur mustard vapor exposure demonstrates our commitment to working closely with our federal partners, including BARDA, to expedite the availability of medical countermeasures essential for managing responses to chemical weapons attacks in both civilian and battlefield settings.”

BARDA’s support for this additional indication began in 2013 as part of the federal government’s effort to repurpose approved drugs and medical products to save lives and reduce injury in an attack on the United States.

This multi-purpose approach has proven to be cost-effective in preparing mass casualty emergencies from chemical, biological, and radiological agents. Repurposing products in widespread use additionally ensures first responders have a familiar product to use in a time of crisis.

Beginning in 2015, BARDA used [Project BioShield](https://www.medicalcountermeasures.gov/barda/cbrn/project-bioshield-overview.aspx) authorities and the Project BioShield Special Reserve Fund to purchase Silverlon for the Strategy National Stockpile as part of BARDA’s burn countermeasure program. BARDA continues to work with Argentum on studies necessary for FDA clearance of Silverlon for use on radiation burns.

Silverlon is a silver-plated nylon dressing available commercially and used widely to aid in the management of acute skin wounds and first- and second-degree thermal burns. The silver plating helps kill bacteria within the dressing, and one dressing can be used for up to seven days. This allows for fewer dressing changes, which reduces the burden on caregivers and minimizes the pain and damage that would occur if the wound was disturbed.

Sulfur mustard was first used as a chemical weapon in World War I and can be released into the air, food or water. More recently the chemical was used in the Iran-Iraq war and in the Syrian Civil War.

 [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [Chemical](https://cbrneworld.com/component/tags/tag/chemical)

       [![](https://cbrneworld.com/images/News-Images/Arizona_State_University.gif)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1349:darpa-awards-grant-to-asu-for-fight-against-wmds-2&catid=12)

##  [DARPA Awards Grant to ASU for Fight Against WMDs](https://cbrneworld.com/index.php?option=com_content&view=article&id=1349:darpa-awards-grant-to-asu-for-fight-against-wmds-2&catid=12)

 Written by Zoe Rutherford on 23 July 2019.

Arizona State University has announced that it has been selected by the U.S. Defense Advanced Research Projects Agency (DARPA) to build a field-deployable, point-of-care device that will determine in 30 minutes or less if a person has been exposed to weapons of mass destruction or their precursors. The DARPA award, worth up to $38.8 million over four years in phases and options, will build on the university’s growing capabilities in developing molecular diagnostics for applications in defense and human health.

The device will be capable of detecting the health effects of a number of substances associated with weapons of mass destruction, including biological agents, radiation, chemicals, and explosives.

Arizona State University has been selected to participate in DARPA’s Epigenetic CHaracterization and Observation (ECHO) program. According to DARPA, the “ECHO program has two primary challenges: to identify and discriminate epigenetic signatures created by exposure to threat agents; and to create technology that performs highly specific forensic and diagnostic analyses to reveal the exact type and time of exposure.” (Epigenetic changes are chemical modifications that affect genes, altering their expression while leaving the genetic code intact. Epigenetic changes can occur as natural responses to the environment but can also signal exposure to toxic agents or disease pathogens.)

pigenetics is coming into its own in the 21st century. DARPA describes the epigenome as “biology’s record keeper,” explaining that “though DNA does not change over a single lifetime, a person’s environment may leave marks on the DNA that modify how that individual’s genes are expressed. This is one way that people can adapt and survive in changing conditions, and the epigenome is the combination of all of these modifications. Though modifications can register within seconds to minutes, they imprint the epigenome for decades, leaving a time-stamped biography of an individual’s exposures that is difficult to deliberately alter.”

Sethuraman Panchanathan, ASU Knowledge Enterprise executive vice president and chief research and innovation officer, said the project fits with the university's mission.

“ASU has long been committed to working across disciplines, often in tandem with corporate partners and government entities, to identify, address and solve global grand challenges,” Panchanathan said. “We’re proud to utilize our innovative approaches to advance our military’s capability in this critical capacity. Warfighting technology of the future will increasingly rely on the ability to rapidly develop and deploy highly integrated, responsive technologies like the ECHO project. Much like ASU, DARPA is committed to making strategic investments in breakthrough technologies. This partnership to advance our country’s national security priorities is a direct reflection of that shared vision.”

The technology under development may eventually enable simple, low-cost monitoring of epigenetic changes, which could be used as a powerful diagnostic method to detect a broad range of human diseases.

The new Translational Center for Molecular Diagnostics within ASU’s [Biodesign Virginia G. Piper Center for Personalized Diagnostics](https://biodesign.asu.edu/personalized-diagnostics) brings together a proven team that includes molecular assay development, bioinformatics, machine learning, biosignature identification and automated assay development. ASU’s approach engages experts both within ASU and externally to leverage maturing technologies that are ready to make an impact in the field.

While available technologies can identify the physical presence of weapons of mass destruction and chemical precursors, current techniques for determining the source of life-threatening substances have proven unsatisfactory at identifying people engaged in the production of toxic agents. The ECHO program assesses the impacts of exposure on the human body. This epigenetic signature provides a persistent indicator of historical exposures.

The ASU team, led by Joshua LaBaer, executive director of the Biodesign Institute and director of the Center for Personalized Diagnostics, and co-principal investigator Vel Murugan, aims to develop a technology that will use a single drop of blood to quickly read a person’s epigenetic “fingerprint.” The fingerprint will identify signatures that indicate if the individual has ever been exposed to materials associated with producing weapons of mass destruction.

The ASU project will be known as DEPICT-Diagnostic Epigenetics of Infectious agents and Chemical Toxicity. During the project, researchers will apply novel approaches to identify changes in global epigenetic signatures and implement unique bioinformatics and machine learning tools to identify epigenetic biomarkers that will quickly and accurately reveal the nature and severity of exposures.

In keeping with their high-risk, high-reward approach to innovation, DARPA envisions the same technology being used to rapidly diagnose patients and troops who may have been exposed to threat agents or who may be suffering from infections.

“ECHO technology could open up new sources of forensic evidence and make battlefield collection of evidence safer, more efficient and more accurate,” Eric Van Gieson, ECHO program manager, said in DARPA’s original announcement of the program. “Additionally, by making it possible to deploy an analytical capability to vastly more locations, we would enhance our ability to conduct global, near-real-time surveillance of emerging threats.”

According to LaBaer, this project builds on the team’s [previous success with a $36 million Biomedical Advanced Research and Development Authority (BARDA) project ](https://biodesign.asu.edu/news/asu-research-project-tackle-nuclear-emergency-moves-product-development-phase)during which his team created a bio-dosimeter that can detect the level of exposure to an unanticipated radiologic or nuclear event. ASU’s prior experience in assay development and translation to industry will be fundamental to the development of this new platform.

“Imagine U.S. intelligence has identified a WMD threat and a suspect, but needs a way to quickly verify if the suspect is the perpetrator,” LaBaer said. “The current approach just isn’t effective. Medical personnel would identify traces of biological or chemical agents on the suspect’s clothing or hair, a slow and unreliable process requiring lab analysis. Now, consider the same situation in which the agent in the field can obtain a small blood sample and check epigenetic markers in real time to begin piecing together evidence.”

Co-principal investigator Murugan said that the molecular diagnostics team at the [Biodesign Institute](https://biodesign.asu.edu/) is driven by the idea their work will save lives.

“We continue to work with institutions across the U.S. and our partners around the world to develop technologies that will protect our warfighters, as well as our fellow citizens,” Murugan said. “The assays and platform that we will develop have the potential to become useful beyond detecting WMD exposures — ultimately, leading to a non-invasive diagnostic test for chronic illnesses such as cancer, diabetes and heart diseases.”

The project will require experts from various disciplines, including epigenomics, genomics, proteomics, single-cell genomics, microfluidics, toxicogenomics, assay development, process optimization, QA/QC, bioinformatics, machine learning algorithm development, instrument design and manufacturing, as well as chemical, biological, radiological and nuclear defense.

The ASU team includes researchers Chad Borges, Michael J. Fiacco, Robert McCulloch, Paul R. Hahn, Jin Park and Mitch Magee.

Jennifer Blain Christen, assistant professor at ASU’s Ira A. Fulton Schools of Engineering and an expert in microfluidics, will be part of an independent advisory panel.

As envisioned by DARPA, the ECHO diagnostic platform could meet the needs of many organizations, including Special Operations Command, Biomedical Advanced Research and Development Authority, U.S. Army Medical Research and Materiel Command, and Joint Program Executive Office for Chemical and Biological Defense.

The interdisciplinary team includes SRI International, Gryphon Scientific, Columbia University, Northern Arizona University and Washington University in Saint Louis.

 [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [Biological](https://cbrneworld.com/component/tags/tag/biological)

       [![](https://cbrneworld.com/images/cows-1209635_1920.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1346:tackling-agro-terrorism&catid=12)

##  [Tackling Agro-Terrorism ](https://cbrneworld.com/index.php?option=com_content&view=article&id=1346:tackling-agro-terrorism&catid=12)

 Written by Zoe Rutherford on 19 July 2019.

Interesting 3 part series on Agro-Terrorism in Bovine Veterinarian [Part 1](https://www.bovinevetonline.com/article/stay-your-guard), [Part 2](https://www.bovinevetonline.com/article/agro-terrorism-triggers-and-tripwires), [Part 3](https://www.bovinevetonline.com/article/tackling-agro-terrorism), by JoAnn Alumbaugh.

 [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [Biological](https://cbrneworld.com/component/tags/tag/biological)

       [![](https://cbrneworld.com/templates/yootheme/cache/17/Ebola_Virus_Particles-17fe26fd.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1345:ebola-outbreak-2018-present-health-information-guide&catid=12)

##  [Ebola Outbreak 2018 - Present Health Information Guide](https://cbrneworld.com/index.php?option=com_content&view=article&id=1345:ebola-outbreak-2018-present-health-information-guide&catid=12)

 Written by Zoe Rutherford on 19 July 2019.

In response to the WHO declaring the Ebola outbreak in the DRC a Public Health Emergency of International Concern (PHEIC), the U.S. National Library of Medicine has made available to all the Ebola Outbreak: 2018-Present Health Information Guide.

The guide can be found [here](https://disasterinfo.nlm.nih.gov/ebola-2018) and contains all the information and links one might need when requiring more information on Ebola.

The PHEIC declaration was made following a meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 17 July 2019, and includes advice for affected countries, neighboring countries, and all states. The statement can be read [here ](https://www.who.int/ihr/procedures/statement-emergency-committee-ebola-drc-july-2019.pdf)

 [Biological](https://cbrneworld.com/component/tags/tag/biological), [Doctrine](https://cbrneworld.com/component/tags/tag/doctrine)

       [![](https://cbrneworld.com/images/News-Images/Bertin.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1343:the-saphygate-g-in-action&catid=12)

##  [The SAPHYGATE G in action ](https://cbrneworld.com/index.php?option=com_content&view=article&id=1343:the-saphygate-g-in-action&catid=12)

 Written by Zoe Rutherford on 18 July 2019.

Watch the SaphyGATE G in action, the environmental monitoring solution for truck, train &amp; cargo radiation control <http://f.info.bertin.fr/o/?s=862-db4f-3EE9-e798dc49-a4f9>

 [Detection](https://cbrneworld.com/component/tags/tag/detection), [Threat](https://cbrneworld.com/component/tags/tag/threat), [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [Radiological](https://cbrneworld.com/component/tags/tag/radiological)

       [![](https://cbrneworld.com/templates/yootheme/cache/40/Dont_Blow_It-40ca1a3f.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1341:don-t-blow-it-phase-2-launch-event&catid=12)

##  [Don’t Blow It! Phase 2 Launch Event.](https://cbrneworld.com/index.php?option=com_content&view=article&id=1341:don-t-blow-it-phase-2-launch-event&catid=12)

 Written by Zoe Rutherford on 17 July 2019.

DASA is inviting expressions of interest for a launch event on 1 October 2019 for our 'Don’t Blow It! Safely eliminating chemical and biological munitions on the battlefield' competition.

This [Defence and Security Accelerator (DASA)](https://www.gov.uk/government/organisations/defence-and-security-accelerator) competition is seeking proposals for novel and innovative technologies and approaches to access, disable and/or irreversibly destroy chemical and biological munitions, improvised explosive devices (IEDs) containing chemical and biological agents, and containers of bulk agents in challenging environments.

Following a successful [Phase 1 competition](https://www.gov.uk/government/publications/dont-blow-it-safely-eliminating-chemical-and-biological-munitions-on-the-battlefield), Phase 2 offers up to £1.5 million to fund emerging innovations at [technology readiness level (TRL)](https://www.gov.uk/guidance/defence-and-security-accelerator-terms-and-conditions-and-contract-guidance) 3 upwards to develop full-scale prototypes. Phase 2 of the competition will launch on 1 October 2019, virtually or at a location in London (to be determined).

This competition is jointly funded by the UK Ministry of Defence and the U.S. Department of Defense, and will operate under an existing memorandum of understanding between both nations.

Under the [Chemical Weapons Convention](#link_tab), all [member states](https://www.opcw.org/about-opcw/member-states/) are obligated to destroy any [chemical weapons](https://www.opcw.org/fileadmin/OPCW/Fact_Sheets/English/Fact_Sheet_4_-_CW_types.pdf) they own or possess, or that they abandoned on the territory of another member state. Whilst destruction technologies exist for this purpose, they are not appropriate for use in all circumstances. Recent events have increased focus on developing a toolkit to enable rapid and effective disablement or irreversible destruction of smaller caches discovered in resource-limited environments.

Through this competition, we will investigate novel or innovative new concepts or adaptions of current technologies. We expect these solutions will ultimately enable more rapid, effective and flexible destruction methods than are used for large stockpiles, and reduce logistical support requirements, whilst maximising ease of operation, transportability and ruggedness of the equipment. These improvements are expected to improve operational flexibility for a wide variety of scenarios.

This competition is focused on three main objectives:

- Access: Gain access to munitions, IEDs and bulk containers without relying on the original design features, such as filling ports
- Disable: Prevent munitions, IEDs and bulk agent being used as intended either temporarily or permanently
- Destroy: Permanently and irreversibly destroy munitions, IEDs and bulk agents

Where Phase 1 funded proposals were focused on single component parts, Phase 2 projects should focus on a system solution either by collaboration with other partners or by integration into existing technologies.

The competition will be formally launched at 13:00 on 1 October 2019. If you are interested in attending an event please register your expression of interest [here](https://www.eventbrite.co.uk/e/dont-blow-it-phase-2-launch-tickets-65539836415) by 14 August 2019 17:00 (BST). Accepted registrants will be sent full details and an agenda.

 [Threat](https://cbrneworld.com/component/tags/tag/threat), [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [Chemical](https://cbrneworld.com/component/tags/tag/chemical), [Biological](https://cbrneworld.com/component/tags/tag/biological)

       [![](https://cbrneworld.com/templates/yootheme/cache/8d/Med-Eng-8d4f62aa.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1340:united-states-marine-corps-selects-med-eng-eod-10-bomb-suit-to-protect-the-lives-of-explosive-ordnance-disposal-specialists&catid=12)

##  [United States Marine Corps Selects Med-Eng EOD 10 Bomb Suit to Protect the Lives of Explosive Ordnance Disposal Specialists ](https://cbrneworld.com/index.php?option=com_content&view=article&id=1340:united-states-marine-corps-selects-med-eng-eod-10-bomb-suit-to-protect-the-lives-of-explosive-ordnance-disposal-specialists&catid=12)

 Written by Zoe Rutherford on 16 July 2019.

[Med-Eng](http://www.med-eng.com/?utm_source=shot2016&utm_medium=post&utm_campaign=eod10), a brand of The Safariland Group, announced today a $10.2M delivery order added to a 2017 contract awarded by the United States Air Force for EOD® 10 Explosive Ordnance Disposal (EOD) suits and helmets. This particular delivery order is for the U.S. Marine Corps with all deliveries being made to their bases across the U.S.

This selection by the Marine Corps completes acceptance by multiple branches of the United States military, including the Marine Corps, Navy, Air Force and Army, of the most current Med-Eng bomb suit ensembles to protect EOD teams for years to come. Earlier in 2019, the Army also selected a unique variation of the EOD 10 suit architecture from Med-Eng, as its second generation Advanced Bomb Suit (ABS II).

The Air Force increased its Indefinite Delivery Indefinite Quantity (IDIQ) contract previously awarded to Med-Eng in March 2017 from $11M to $26.5M to allow the Marine Corps to utilize its contract vehicle already procuring EOD 10 ensembles for the Air Force.

“The joint effort between the Air Force and the Marine Corps shows the collaboration across the Department of Defense and the trust and confidence they have in Med-Eng equipment,” said Rob Reynolds, General Manager of Med-Eng. “Overall, it is very encouraging to see how widely the EOD 10 has been adopted and successfully deployed by military, federal and public safety teams across the nation and in 45 countries worldwide.”

The suit and helmet ensembles will be made using the skilled workforce at the Med-Eng production facility in Ogdensburg, New York. Using the Lean manufacturing process, this facility operates under a registered ISO:9001 Quality Management System and is fully compliant with the manufacturing requirements of the National Institute of Justice (NIJ) standard 0117.01 for public safety bomb suits. It has been making blast protective suits for the military, as well as federal and public safety agencies, for more than 10 years.

Brad Williams, president of The Safariland Group, commented, “This is a significant contract win that will bring direct economic benefits to northern New York, including increased employment. Combined with other recent contract awards, we have a very strong basis for expanding our Ogdensburg facility to meet the steady demand for our protective equipment.”

“This is an important milestone in the history of providing personal protection to American EOD operators,” added Reynolds. “A new generation of Med-Eng bomb suits will be entrusted to protect all U.S. military EOD operators against explosive threats, including Improvised Explosive Devices (IEDs).”

 [Equipment](https://cbrneworld.com/component/tags/tag/equipment), [Contract](https://cbrneworld.com/component/tags/tag/contract), [EOD](https://cbrneworld.com/component/tags/tag/eod)

       [![](https://cbrneworld.com/templates/yootheme/cache/5c/Rigaku_-_Detectachem-5c2841ac.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1339:rigaku-analytical-devices-inc-and-detectachem-inc-have-completed-testing-of-their-integrated-trace-and-bulk-explosive-detection-solution-in-partnership-with-the-transportation-security-administration-tsa&catid=12)

##  [Rigaku Analytical Devices, Inc. and DetectaChem, Inc. Have Completed Testing of Their Integrated Trace and Bulk Explosive Detection Solution in Partnership with the Transportation Security Administration (TSA)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1339:rigaku-analytical-devices-inc-and-detectachem-inc-have-completed-testing-of-their-integrated-trace-and-bulk-explosive-detection-solution-in-partnership-with-the-transportation-security-administration-tsa&catid=12)

 Written by Zoe Rutherford on 16 July 2019.

*Rigaku and DetectaChem chemical identification technologies are integrated into a single handheld solution to deliver advanced automated trace and bulk explosive detection and chemical analysis capabilities.*

– [Rigaku Analytical Devices, Inc.](https://www.rigaku.com/en/handhelds) a leader in handheld and portable Raman analyzers, together with [DetectaChem, Inc.](https://detectachem.com/), with its innovative advanced automated colorimetric solutions, announce the demonstration of their new integrated next-generation alarm resolution and chemical analysis solution with [TSA](https://www.tsa.gov/) at the following facilities:

1. Dallas/Fort Worth International Airport (DFW)
2. Ronald Reagan Washington National Airport (DCA)
3. Washington Dulles International Airport (IAD)
4. TSA Transportation Security Operations Center

*“Rigaku and DetectaChem have joined forces to integrate, in a single device, two high-performance threat detection, and identification technologies,”* said Bree Allen, President of Rigaku Analytical Devices.

*“Our work with TSA’s Innovation Task Force allowed us the opportunity to deliver both advanced next-generation automated colorimetrics and Raman spectroscopy to transportation security operations in a single, high-performance integrated and automated solution,”* said DetectaChem’s CEO, Travis Kisner.

Rigaku and DetectaChem’s integrated solution, like other Innovation Task Force demonstrations, provided airport stakeholders, TSA officers, and industry with valuable user feedback and operational experience to support the development of cutting-edge and robust detection capabilities to address new and emerging security threats.

More information about this integrated detection device from Rigaku is available at [www.rigaku.com/QuickDetect](http://www.rigaku.com/QuickDetect)

More information about detection technology from DetectaChem is available at <https://detectachem.com/applications/explosive-detection>

 [Detection](https://cbrneworld.com/component/tags/tag/detection), [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne)

       [![](https://cbrneworld.com/templates/yootheme/cache/65/Tracie_logo-6528b391.png)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1338:new-paper-released-by-aspr-tracie-mass-casualty-trauma-triage-paradigms-and-pitfalls&catid=12)

##  [New Paper released by ASPR TRACIE: Mass Casualty Trauma Triage Paradigms and Pitfalls](https://cbrneworld.com/index.php?option=com_content&view=article&id=1338:new-paper-released-by-aspr-tracie-mass-casualty-trauma-triage-paradigms-and-pitfalls&catid=12)

 Written by Zoe Rutherford on 16 July 2019.

The Technical Resources, Assistance Center, and Information Exchange (TRACIE) has released a new paper entitled Mass Casualty Trauma Triage Paradigms and Pitfalls.

The focus of this paper is to alert EMS medical directors and EMS systems planners, and hospital emergency planners to key differences between “conventional” mass casualty incidents and mass violence events when: the scene is dynamic; the number of patients far exceeds usual resources, and usual triage and treatment paradigms may fail or be insufficient.

The paper is free and can be accessed [here](https://files.asprtracie.hhs.gov/documents/aspr-tracie-mass-casualty-triage-final-508.pdf)

 [Training](https://cbrneworld.com/component/tags/tag/training), [Doctrine](https://cbrneworld.com/component/tags/tag/doctrine), [First Responder](https://cbrneworld.com/component/tags/tag/first-responder)

       [![](https://cbrneworld.com/templates/yootheme/cache/47/DHS_ST-47bed3b1.png)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1337:dhs-s-t-announces-35m-funding-opportunity-for-new-center-of-excellence-in-terrorism-prevention-and-counterterrorism-research&catid=12)

##  [DHS S&amp;T Announces $35M Funding Opportunity for New Center of Excellence in Terrorism Prevention and Counterterrorism Research](https://cbrneworld.com/index.php?option=com_content&view=article&id=1337:dhs-s-t-announces-35m-funding-opportunity-for-new-center-of-excellence-in-terrorism-prevention-and-counterterrorism-research&catid=12)

 Written by Zoe Rutherford on 16 July 2019.

The Department of Homeland Security (DHS) [Science and Technology Directorate](https://www.dhs.gov/science-and-technology) (S&amp;T) announced today $35 million in funding opportunities for a new DHS [Center of Excellence](https://www.dhs.gov/science-and-technology/centers-excellence) (COE) for Terrorism Prevention and Counterterrorism Research (TPCR). Accredited United States colleges and universities are invited to submit proposals as the center lead or as an individual partner to work with the lead institution in support of the center’s activities.

“By partnering with universities, S&amp;T delivers practical results by developing multidisciplinary, customer-driven solutions while training the next generation of homeland security experts,” said William Bryan, Senior Official Performing the Duties of the Under Secretary for Science and Technology. “Once awarded, this COE will leverage emerging technologies and analytic techniques to provide innovative solutions for preventing and countering terrorism.”

This funding opportunity is posted at <http://www.grants.gov/>. The deadline for submitting proposals is September 6, 2019**.** DHS plans to fund this new COE through a cooperative agreement for 10 years for a total of approximately $35 million.

The TPCR COE will research and develop solutions to support DHS counterterrorism operations. This includes solutions that help prevent terror attacks by countering the radicalization of people and their mobilization to violence. TPCR will also educate a skilled workforce trained in the latest methods to identify and protect the nation from terrorist threats.

The rapidly-evolving, diverse terrorist threat continually exploits technological advances to adapt the nature and expand the reach of its tactics. TPCR will support academic-led innovation that supports DHS in staying a step ahead of emerging terrorist tactics.

DHS is soliciting proposals from multi-disciplinary research and education teams that will work closely with DHS and other subject-matter experts to develop successful innovations to confront the future counterterrorism challenges DHS faces. The teams will need various combinations of academic disciplines, including engineering, data analytics, and mathematics.

The DHS COEs are university consortia that work closely with DHS operating components to research, develop, and transition mission-relevant science and technology, and to educate the next generation of homeland security technical experts. TPCR will be required to engage with DHS operational components and fully understand the operational environment to help better identify technical and training gaps. Each DHS COE is led by a U.S. college or university and has multiple partners from universities, commercial industry, DHS, Federally Funded Research and Development Centers, and other federal, state, and local agencies.

The notice of funding opportunities for the Terrorism Prevention and Counterterrorism Research COE [Lead Institution](https://www.grants.gov/web/grants/view-opportunity.html?oppId=318277) and [Partner Institution](https://www.grants.gov/web/grants/view-opportunity.html?oppId=318279) are available at [grants.gov](http://www.grants.gov/). S&amp;T will conduct an informational webinar for interested applicants on August 6, 2019 at 3 p.m. EDT. During the call, DHS will discuss the notice of funding opportunity and provide an opportunity for interested applicants to ask questions. The webinar can be accessed at <https://share.dhs.gov/rwo6kbeg53be/>; it will be recorded and posted on [www.grants.gov](http://www.grants.gov/) for future reference.

For additional information about the DHS COEs, visit [DHS Centers of Excellence](https://www.dhs.gov/st-centers-excellence).

 [Funding ](https://cbrneworld.com/component/tags/tag/funding)

       [![](https://cbrneworld.com/templates/yootheme/cache/77/DroneGun_MKII-7764b5a4.png)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1334:droneshield-releases-dronegun-mkiii&catid=12)

##  [DroneShield releases DroneGun MKIII](https://cbrneworld.com/index.php?option=com_content&view=article&id=1334:droneshield-releases-dronegun-mkiii&catid=12)

 Written by Zoe Rutherford on 15 July 2019.

DroneShield Ltd is pleased to release a breakthrough new product, DroneGun MKIII, following extensive development in response to end-user feedback. The product is available for purchase from today to qualified end-users, where lawful.

 DroneGun MKIII is a portable pistol-shape drone jammer, weighing under 2kg. The Company believes this product is peerless globally, for its combination of size and effectiveness.

DroneGun MKIII is designed to be an alternate rather than a replacing product for its highly successful DroneGun TacticalTM unit, having a shorter effective range of 500m versus 1-2km for DroneGun TacticalTM.

 DroneGun MKIIIcan also be used in combination with other DroneShield products, including the RfPatrolTM body-worn detection device and the DroneSentinelstationary multi-sensor detection system.

 Product overview can be found [here](https://droneshield.us13.list-manage.com/track/click?u=b08000de91c728bc643773cef&id=857ed8873d&e=2143dbd8e0).

 [Drone](https://cbrneworld.com/component/tags/tag/drones), [Technology](https://cbrneworld.com/component/tags/tag/technology), [Tactical](https://cbrneworld.com/component/tags/tag/tactical)

       [![](https://cbrneworld.com/images/events/sponsor_logos/RapiscanSystems_logo_re-sized.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1333:rapiscan-systems-metor-6e-achieves-ecac-performance-standard&catid=12)

##  [Rapiscan Systems Metor 6E achieves ECAC performance standard](https://cbrneworld.com/index.php?option=com_content&view=article&id=1333:rapiscan-systems-metor-6e-achieves-ecac-performance-standard&catid=12)

 Written by Zoe Rutherford on 12 July 2019.

Rapiscan Systems, a leading global supplier of security inspection technology, today announced that its Metor 6E people screening solution has achieved the European Civil Aviation Conference (ECAC) and European Union (EU) performance standard for walk-through metal detectors.

 ECAC has established a Common Evaluation Process (CEP) and standards for testing security equipment. Passing the performance standard for walk-through metal detectors signifies that the Metor 6E can be used in airports within the ECAC/EU.

 Rapiscan’s Metor 6E is a state-of-the-art walk-through metal detector, built to support the most demanding and high-traffic security screening environments. Designed with advanced features including automatic interactive sensitivity adjustment, automatic frequency selection, power guard and violation monitoring, the Metor 6E delivers powerful screening for airport checkpoints. The sleek, easy-to-install system was developed to comply with internationally recognized aviation requirements, and to integrate seamlessly into high-risk security infrastructures.

 “Achieving this performance standard is a great accomplishment for the Rapiscan team, and demonstrates our commitment to investing in the highest quality technologies,” said Mal Maginnis of Rapiscan Systems. “Many customers around the world rely on the ECAC/EU when setting their own standards and now will be able to acquire the Metor 6E.”

 For more information on Rapiscan Systems visit their website [here](https://www.rapiscansystems.com/en/).

 [Detection](https://cbrneworld.com/component/tags/tag/detection), [Security](https://cbrneworld.com/component/tags/tag/security)

       [![](https://cbrneworld.com/templates/yootheme/cache/8a/Cepi_Wageningen-8abcee35.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1332:cepi-awards-contract-to-consortium-to-develop-a-human-vaccine-against-rift-valley-fever&catid=12)

##  [CEPI awards contract to consortium to develop a human vaccine against Rift Valley fever](https://cbrneworld.com/index.php?option=com_content&view=article&id=1332:cepi-awards-contract-to-consortium-to-develop-a-human-vaccine-against-rift-valley-fever&catid=12)

 Written by Zoe Rutherford on 11 July 2019.

CEPI has awarded a contract worth up to US$12.5 million to a consortium led by Wageningen Bioveterinary Research to develop a human vaccine against Rift Valley fever.

Wageningen Bioveterinary Research (WBVR), part of Wageningen University &amp; Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new partnering agreement. With support from the European Union’s (EU’s) Horizon 2020 programme, CEPI will provide up to US$12.5 million for vaccine manufacturing, preclinical research, and a phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose vaccine candidate (RVFV-4s) against Rift Valley fever virus for use in humans. WBVR will lead a consortium of research, manufacturing, and clinical evaluation organizations to undertake this project.

To produce this vaccine candidate, researchers at WBVR have altered the genome of the Rift Valley fever virus in a way that significantly weakens it. This “attenuated” virus will be used as a vaccine to generate a lasting immune response against the disease. This investment is part of CEPI’s third call for proposals, launched earlier this year with support from the EU’s Horizon 2020 research and innovation programme under [grant agreement No. 857934](https://cepi.net/news_cepi/cepi-launches-call-for-proposals-to-develop-vaccines-against-rift-valley-fever-and-chikungunya-viruses/).

 [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological), [Contract](https://cbrneworld.com/component/tags/tag/contract)

## Schema

```json
{ "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" } ] }
```